公开(公告)号：US20230026438A1

公开(公告)日：2023-01-26

申请号：US17830185

申请日：2022-06-01

Applicant: ACEA Therapeutics, Inc.

Inventor： Long Mao ,  Xiao Xu ,  Namir Shaabani ,  Can Jin

IPC: C07D207/26 ,  C07D403/12 ,  C07D413/14 ,  C07D401/12 ,  C07D403/14 ,  C07D401/14 ,  C07D207/416

Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

公开(公告)号：US11612602B2

公开(公告)日：2023-03-28

申请号：US17001147

申请日：2020-08-24

Applicant: ACEA Therapeutics, Inc.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A61K31/519 ,  C07D403/12 ,  A61P35/00 ,  A61K31/52 ,  C07D473/32 ,  A61K31/506 ,  C07D487/04 ,  C07D401/14 ,  C07D473/34 ,  A61K45/06 ,  C07D239/48 ,  C07D473/24 ,  C07D239/46 ,  C07D473/40 ,  C07D239/42 ,  C07D487/02 ,  C07D473/16 ,  C07D239/47 ,  C07D401/12

Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US11498922B2

公开(公告)日：2022-11-15

申请号：US16500384

申请日：2017-04-07

Applicant: ACEA Therapeutics, Inc. ,  Hangzhou ACEA Pharmaceutical Research Co., Ltd. ,  Zhejiang ACEA Pharmaceuticals Co., Ltd

Inventor： Long Mao ,  Jia Liu ,  Yile Chen ,  Yuning Hua ,  Kongen Dai ,  Yimei Bao ,  Bojie Weng ,  Xi-aopeng Mo ,  Jian Wu ,  Xiao Xu ,  Wanhong Xu ,  Xiaobo Wang

IPC: A61K31/519 ,  C07D487/04 ,  A61K9/00 ,  A61K9/20

Abstract: The present invention relates to methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.

公开(公告)号：US20210309642A1

公开(公告)日：2021-10-07

申请号：US17266075

申请日：2018-08-09

Applicant: ACEA Therapeutics, Inc. ,  HANGZHOU ACEA PHARMACEUTICAL RESEARCH CO., LTD ,  ZHEJIANG ACEA PHARMACEUTICALS CO., LTD.

Inventor： Long MAO ,  Jia LIU ,  Yile CHEN ,  Yuning HUA ,  Kunhua DONG ,  Liang CHEN ,  Bojie WENG ,  Xiaopeng MO ,  Kongen DAI ,  Yimei BAO ,  Jian WU ,  Bin LIANG ,  Guanglin ZHOU ,  Zhen WANG

IPC: C07D403/12 ,  A61K9/48 ,  A61K9/20 ,  A61K9/28

Abstract: The invention relates to solid forms of certain N-(pyrimidinyloxy)acrylamide derivatives that are useful in the treatment of proliferation and immunological disorders and other diseases related to the dysregulation of kinases including EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK. The invention provides methods of making these materials and their salts and polymorphs, and intermediates for preparing these materials, as well as pharmaceutical compositions comprising these materials. The solid forms and pharmaceutical compositions comprising them are useful to treat conditions including a proliferation disorder, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye, rheumatoid arthritis, or lupus.

公开(公告)号：US20180312510A1

公开(公告)日：2018-11-01

申请号：US15766736

申请日：2016-06-30

Applicant: ACEA THERAPEUTICS, INC.

Inventor： Long MAO ,  Jia LIU ,  Yile CHEN ,  Yuning HUA ,  Kongen DAI ,  Yimei BAO ,  Bojie WENG ,  Xiaopeng MO ,  Jian WU ,  Xiao XU ,  Wanhong XU ,  Xiaobo WANG

IPC: C07D487/04 ,  A61K9/48 ,  A61K9/20

Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.

公开(公告)号：US10562918B2

公开(公告)日：2020-02-18

申请号：US15882924

申请日：2018-01-29

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: C07D519/00 ,  C07D403/12 ,  C07D417/12 ,  C07D473/18 ,  C07D487/04 ,  C07D401/12 ,  C07D239/52 ,  C07D239/49 ,  C07D239/48 ,  C07D239/47

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

公开(公告)号：US20250122153A1

公开(公告)日：2025-04-17

申请号：US18642453

申请日：2024-04-22

Applicant: ACEA Therapeutics, Inc.

Inventor： Long Mao ,  Xiao Xu ,  Namir Shaabani ,  Can Jin

IPC: C07D207/26 ,  C07D207/416 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

公开(公告)号：US20230322668A1

公开(公告)日：2023-10-12

申请号：US18210555

申请日：2023-06-15

Applicant: ACEA Therapeutics, Inc.

Inventor： Long Mao ,  Xiao Xu ,  Namir Shaabani ,  Can Jin

IPC: C07D207/26 ,  C07D207/416 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

CPC classification number: C07D207/26 ,  C07D207/416 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)




and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

公开(公告)号：US20210100802A1

公开(公告)日：2021-04-08

申请号：US17001147

申请日：2020-08-24

Applicant: ACEA Therapeutics, Inc.

Inventor： Xiao XU ,  Xiaobo WANG ,  Long MAO ,  Li ZHAO ,  Biao XI

IPC: A61K31/519 ,  A61K31/52 ,  C07D473/32 ,  A61K31/506 ,  C07D487/04 ,  C07D401/14 ,  C07D403/12 ,  C07D473/34 ,  A61K45/06 ,  C07D239/48 ,  C07D473/24 ,  C07D239/46 ,  C07D473/40 ,  C07D239/42 ,  C07D487/02 ,  C07D473/16 ,  C07D239/47 ,  C07D401/12

Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US20250136576A1

公开(公告)日：2025-05-01

申请号：US18578240

申请日：2022-07-12

Applicant: ACEA Therapeutics, Inc. ,  Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Inventor： Long Mao ,  Wei Tang ,  Xiaoying Zhang ,  Rongda Xu ,  Yile Chen ,  Xiao Xu ,  Changxu Xu

IPC: C07D401/12 ,  C07D471/04 ,  C07D491/048

Abstract: The present disclosure relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods comprising a compound of any one of Formulas (I), (II), (III), and (IV) as further described herein. The compounds are inhibitors of protein kinases associated with cancers, and are thus useful for the treatment and/or prevention of a tumor or cancer.